Related Experiment Video

Updated: Jun 5, 2026

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

Management of invasive fungal infections: a role for polyenes

Pranatharthi Chandrasekar1

  • 1Wayne State University School of Medicine, Detroit, MI, USA. pchandrasekar@med.wayne.edu

The Journal of Antimicrobial Chemotherapy
|December 22, 2010
PubMed

Insights

The landscape of invasive fungal infections (IFIs) is changing, presenting challenges for clinicians managing immunocompromised patients. This review discusses antifungal treatments, including older polyenes, for effective IFIs management.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Invasive fungal infections (IFIs) pose significant challenges, especially in immunocompromised patients.
  • The emergence of rare and resistant fungal pathogens complicates IFIs management.
  • Early and accurate antifungal therapy is crucial for successful treatment outcomes.

Purpose of the Study:

  • To review current challenges and therapeutic strategies for invasive fungal infections.
  • To highlight the role of various antifungal drug classes in managing IFIs.
  • To provide clinicians with essential considerations for treating IFIs.

Main Methods:

  • Literature review of antifungal drug classes and their application in IFIs.
  • Analysis of treatment options for common and emerging fungal pathogens.
  • Discussion of the clinical utility of polyenes, azoles, and echinocandins.

Main Results:

  • The spectrum of IFIs is evolving with new resistant pathogens.
  • Newer triazoles and echinocandins have altered treatment paradigms for infections like aspergillosis and candidiasis.
  • Older polyene antifungals remain vital due to broad-spectrum activity and low resistance rates, especially in high-risk patients.

Conclusions:

  • Effective management of IFIs requires clinicians to navigate evolving pathogens and treatment options.
  • Despite newer agents, polyenes maintain a critical role in treating IFIs in immunocompromised individuals.
  • This review emphasizes key considerations for optimizing antifungal therapy in IFIs.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Overview of Fungi01:29

Overview of Fungi

Fungi are a diverse group of eukaryotes more closely related to animals than other eukaryotes. Fungal cell walls comprise chitin, a polysaccharide that provides structural strength, and glucans, which contribute to flexibility and integrity. Other polysaccharides, such as mannans and galactosans, may supplement or replace chitin in some fungi. These adaptations, along with their preference for acidic environments and tolerance for high osmotic pressure, enable fungi to thrive in various...
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).